All In Biotech

Drug Trial Radar · NCT05572970

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2022

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.

Conditions

  • Cancer

Interventions

  • BalstilimabDrug

    An anti-programmed death 1 (PD-1) monoclonal antibody.

  • ZalifrelimabDrug

    An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Available

  • Arizona Oncology Associates

    Tucson, Arizona · Available

  • Hoag Gynecologic Oncology

    Newport Beach, California · Available

  • University of California, San Francisco Medical Center

    San Francisco, California · Available

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Available

  • Women & Infants Hospital of Rhode Island

    Providence, Rhode Island · Available

  • Texas Oncology

    Flower Mound, Texas · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.